This is the one to act on. Payless Compounders recalled lots of a compounded semaglutide injectable — the GLP-1 behind the weight-loss boom — combined with glycine and B12.
If your practice offers compounded semaglutide or tirzepatide, stop and check: do any of your vials trace to this compounder or these lots? Pull them, quarantine them, and confirm against the official notice before you draw up another dose. Then document what you found.
The wider signal matters as much as the specific recall. With the FDA's shortage designation for semaglutide gone, compounded GLP-1 has lost much of its legal cover, and recalls and enforcement in this space are climbing. If your weight-loss revenue leans on compounded product, now is the moment to pressure-test your 503A/503B sourcing, your consent language, and your plan B if that supply gets cut off.
The lot numbers and recall reason are in the official FDA notice.
View the official FDA record ↗
This post summarizes a public FDA database entry for medical-aesthetics owners. It is general business information, not medical, legal, or regulatory advice. Always confirm scope, lot numbers, and classification against the official FDA record, and consult your own clinician or counsel for anything clinical or compliance-related.